Engineered nanovesicles designed to target the m6A writer METTL3 reduced neuroinflammation in cell and animal models, according to a Nature Communications study led by Xu, Pan, Li and colleagues. The work leverages an m6A (N6-methyladenosine) pathway intervention—m6A is a common RNA modification regulating gene expression through methylation. The results describe a delivery strategy intended to modulate inflammatory signaling at the RNA level rather than via classical receptor blockade. The authors report effects spanning cultured systems and in vivo models, framing the METTL3 axis as a potential druggable node in neuroinflammatory disease biology. For biotech R&D, the study strengthens the case for therapeutic RNA-modification modulation using targeted nanocarriers as a platform concept.